Fragile X Syndrome Treatment with MC01CI Study

Clinical Trial Title

A six-week, randomized, multicenter, double-blind, parallel, flexed- and fixed-dose study of MC01CI (Metadoxine Extended-Release) 700 mg and 1400 mg compared with placebo in adults and adolescents with fragile X syndrome

Contact Information

Crystal Hervey

Clinical Trial Protocol Description:

The purpose of this study is to evaluate the effects of the investigational drug metadoxine extended release (MDX) on attention deficit symptoms. Attention deficit is a common symptom often associated with fragile X syndrome.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Be between ages 15 and 55.
  • Be available for 84 days (12 weeks), including follow-up examinations.

This is a partial list of inclusion criteria.

Study Details

Contact Information

Crystal Hervey

(312) 942-7250


RUSH University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more